Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $176.5M | $267.2M | $313.8M | $70.1M | $82.1M | |
| Gross Profit | $115.7M | $192.1M | $235.9M | $52.1M | $61.9M | |
| Operating Income | -$9.4M | $57.3M | $76.3M | $15.2M | $18.8M | |
| EBITDA | -$3.8M | $65.1M | $86.9M | $17.8M | $21.5M | |
| Diluted EPS | -$0.12 | $0.07 | $0.09 | $0.04 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $159.2M | $218.4M | $225.6M | $327.7M | $358.8M | |
| Total Assets | $238.2M | $293.8M | $320.3M | $464.2M | $494.6M | |
| Current Liabilities | $50M | $59.6M | $96.4M | $72.1M | $109.1M | |
| Total Liabilities | $422.9M | $531.5M | $572.1M | $674.1M | $539.2M | |
| Total Equity | -$184.7M | -$237.7M | -$251.8M | -$209.9M | -$44.6M | |
| Total Debt | $287.5M | $383.6M | $382.4M | $344.9M | $187.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.9M | $41.2M | $48.2M | $9.3M | $23.5M | |
| Cash From Investing | $20.9M | -$152.8M | $35.4M | -$41.3M | -$25.1M | |
| Cash From Financing | -$2.1M | $91.6M | -$18.6M | -$2.3M | $72M | |
| Free Cash Flow | -$31.8M | $28.5M | $42.7M | $7.8M | $22.4M | |
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.
In the current month, MNKD has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNKD average analyst price target in the past 3 months is $9.61.
According to analysts, the consensus estimate is that MannKind Corp. share price will rise to $9.61 per share over the next 12 months.
Analysts are divided on their view about MannKind Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MannKind Corp. is a Sell and believe this share price will drop from its current level to $7.50.
The price target for MannKind Corp. over the next 1-year time period is forecast to be $9.61 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for MannKind Corp. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
You can purchase shares of MannKind Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MannKind Corp. shares.
MannKind Corp. was last trading at $5.94 per share. This represents the most recent stock quote for MannKind Corp.. Yesterday, MannKind Corp. closed at $5.93 per share.
In order to purchase MannKind Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Market Cap: $4.5T
P/E Ratio: 63x
Market Cap: $4T
P/E Ratio: 36x
Market Cap: $3.8T
P/E Ratio: 39x
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
UniFirst Corp. [UNF] is up 0.77% over the past day.